Leerink Swann lowered shares of BioNTech (NASDAQ:BNTX) from an outperform rating to a market perform rating in a research report released on Friday, 24/7 WallStreet reports. They currently have $31.00 price target on the stock. The analysts noted that the move was a valuation call.

Several other equities analysts have also issued reports on BNTX. Zacks Investment Research lowered shares of BioNTech from a buy rating to a hold rating in a report on Wednesday, January 15th. Bank of America started coverage on shares of BioNTech in a report on Monday, November 4th. They issued a buy rating and a $21.00 target price on the stock. Canaccord Genuity started coverage on shares of BioNTech in a report on Monday, November 4th. They issued a buy rating and a $22.00 target price on the stock. Wolfe Research started coverage on shares of BioNTech in a report on Tuesday, November 5th. They issued an outperform rating and a $21.00 target price on the stock. Finally, Svb Leerink initiated coverage on shares of BioNTech in a report on Monday, November 4th. They issued an outperform rating on the stock. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $28.22.

BNTX stock opened at $33.20 on Friday. BioNTech has a 12-month low of $12.52 and a 12-month high of $48.85. The firm has a fifty day moving average price of $35.30.

BioNTech (NASDAQ:BNTX) last released its earnings results on Thursday, November 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The firm had revenue of $31.87 million during the quarter, compared to analyst estimates of $28.83 million. Equities analysts expect that BioNTech will post -0.79 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer.

Featured Story: S&P 500 Index

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.